Abstract
Different defects in Fas/APO-1 interaction with its ligand or in signaling of apoptosis may contribute to autoimmune disease. The aim of this study was to examine whether elevated serum-soluble Fas (sFas) levels are associated with rheumatoid arthritis (RA) or systemic sclerosis (SSc). sFas level was assayed using a sandwich ELISA in serum from 37 patients with RA, 30 patients with SSc and 20 healthy controls. The RA patients were classified according to disease activity, anatomical joint damage, and the presence of pulmonary involvement. Presence of pulmonary fibrosis, CO diffusion capacity (DLCO) and skin score were determined in patients with SSc. Serum sFas levels were not significantly different between study groups. Serum sFas level in the active RA patients was significantly higher than in the patients with inactive disease (p<0.05). The untreated active RA patients had significantly higher sFas level than healthy controls (p<0.05). In RA patients, sFas level was significantly correlated with rheumatoid factor titer (p=0.01), C-reactive protein (p<0.05), and erythrocyte sedimentation rate (p<0.05). The RA patients with severe joint damage had significantly higher sFas level than those with mild joint damage (p<0.05). The untreated SSc patients had significantly higher sFas levels than the treated SSc patients and healthy controls (p<0.01). Serum sFas level was not correlated with presence of pulmonary fibrosis, DLCO or skin score. The soluble Fas molecule may provide a useful additional marker for assessment of disease activity and severity in patients with RA.
Similar content being viewed by others
Abbreviations
- CRP:
-
C-reactive protein
- DLCO:
-
CO diffusion capacity
- ESR:
-
Erythrocyte sedimentation rate
- RA:
-
Rheumatoid arthritis
- RF:
-
Rheumatoid factor
- sFas:
-
Serum-soluble Fas
- SSc:
-
Systemic sclerosis
References
Mountz JD, Wu J, Cheng J, Zhou T (1994) Autoimmune disease: A problem of defective apoptosis. Arthritis Rheum 37: 1415–1420
Williams GT (1994) Apoptosis in the immune system. J Pathol 173: 1–4
Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin KM (1994) Regulation of apoptosis in the immune system. Curr Opin Immunol 6: 279–289
Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314–317
Adachi M, Watanaba-Fukunaga R, Nagata S (1993) Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 90: 1756–1761
Nagata S, Suda T (1995) Fas and Fas-ligand: lpr and gld mutations. Immunol Today 16: 39–43
Cheng J, Zhou T, Liu C et al. (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759–1762
Mysler E, Bini P, Drappa J et al. (1994) The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 93: 1029–1034
Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas Ligand in rheumatic diseases. Arthritis Rheum 40: 1126–1129
Nakajima T, Aono H, Hasunuma T et al. (1995) Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 38: 485–491
Firestein G, Yeo M, Zvaifler N (1995) Apoptosis in rheumatoid arthritis synovium. J Clin Invest 96: 1631–1638
Hasunuma T, Kayagaki N, Asahara H et al. (1997) Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 40: 80–86
Hasunuma T, Hoa TTM, Aono H et al. (1996) Induction of Fas-dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis. Int Immunol 8: 1595–1602
Kahari VM (1993) Activation of dermal connective tissue in scleroderma. Ann Med 25: 511–518
Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98: 785–792
Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP (1984) Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 27: 645–653
Gustaffsson R, Tötterman TH, Klareskog L, Hallgren R (1990) Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis. Ann Rheum Dis 49: 40–49
Needleman BW, Ordonez JV, Taramelli D, Alms W, Gayer K, Choi J (1990) In vitro identification of a subpopulation of fibroblasts that produces high levels of collagen in scleroderma patients. Arthritis Rheum 33: 842–852
Arnett FC, Edworthy SM, Bloch DA et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315–324
Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee (1980) Preliminary criteria for the classification of systemic sclerosis (Scleroderma). Arthritis Rheum 23: 581–590
Pinals RS, Masi AT, Larsen RA (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24: 1308–1315
Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 18: 481–491
Kahaleh MB, Sultany GI, Smith EA, Huffstutter JE, Loadholt B, LeRoy EC (1986) A modified scleroderma skin scoring method. Clin Exp Rheumatol 4: 367–369
Christensson M, Pettersson E, Eneslatt K et al. (2002) Serum sFas levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. J Clin Immunol 22: 220–227
Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB (1995) Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38: 1735–1737
Goel N, Ulrich DT, Clair WS, Fleming JA, Lynch DH, Seldin MF (1995) Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 38: 1738–1743
Fujihara T, Takeuchi T, Tsubota K et al.(1998) Serum soluble Fas/APO-1 is increased in patients with primary Sjogren’s syndrome. Clin Rheumatol 17: 496–499
Utz PJ, Anderson P (1998) Posttransplantation protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 41: 1152–1160
Hashimoto H, Tanaka M, Suda T et al. (1998) Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 41: 657–662
Wetzig T, Petri JB, Mittag M, Haustein UF (1998) Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis. Arch Dermatol Res 290: 187–190
Stummvoll GH, Aringer M, Smolen JS et al. (2000) Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology 39: 1341–1350
Tomokuni A, Aikoh T, Matsuki T et al.(1997) Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol 110: 303–309
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ateş, A., Kinikli, G., Turgay, M. et al. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin Rheumatol 23, 421–425 (2004). https://doi.org/10.1007/s10067-004-0909-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-004-0909-4